Manic switch and serotonin syndrome with venlafaxine-lithium-valproate association.
Liberek
Christophe
C
Aubry
Jean-Michel
JM
Baud
Patrick
P
D000328:Adult; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000523:psychology; D004338:Drug Combinations; D006801:Humans; D008297:Male; D020230:Serotonin Syndrome / Q000523:psychology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D000069470:Venlafaxine Hydrochloride
D018692:Antimanic Agents; D003511:Cyclohexanols; D004338:Drug Combinations; D017367:Selective Serotonin Reuptake Inhibitors; D014635:Valproic Acid; D000069470:Venlafaxine Hydrochloride